Literature DB >> 29290629

Remission is good - relapse is bad.

Paul S Gaynon1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29290629      PMCID： PMC5777185          DOI： 10.3324/haematol.2017.182667

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation.

Authors:  P Lucio; G Gaipa; E G van Lochem; E R van Wering; A Porwit-MacDonald; T Faria; E Bjorklund; A Biondi; M W van den Beemd; E Baars; B Vidriales; A Parreira; J J van Dongen; J F San Miguel; A Orfao
Journal:  Leukemia       Date:  2001-08       Impact factor: 11.528

2.  Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.

Authors:  Nicola Gökbuget; Michael Kneba; Thorsten Raff; Heiko Trautmann; Claus-Rainer Bartram; Renate Arnold; Rainer Fietkau; Mathias Freund; Arnold Ganser; Wolf-Dieter Ludwig; Georg Maschmeyer; Harald Rieder; Stefan Schwartz; Hubert Serve; Eckhard Thiel; Monika Brüggemann; Dieter Hoelzer
Journal:  Blood       Date:  2012-03-22       Impact factor: 22.113

Review 3.  Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.

Authors:  Gautam Kishore Valecha; Uroosa Ibrahim; Sassine Ghanem; Divya Asti; Jean-Paul Atallah; Terenig Terjanian
Journal:  Expert Rev Hematol       Date:  2017-07-10       Impact factor: 2.929

4.  Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.

Authors:  Lenka Hovorkova; Marketa Zaliova; Nicola C Venn; Kirsten Bleckmann; Marie Trkova; Eliska Potuckova; Martina Vaskova; Jana Linhartova; Katerina Machova Polakova; Eva Fronkova; Walter Muskovic; Jodie E Giles; Peter J Shaw; Gunnar Cario; Rosemary Sutton; Jan Stary; Jan Trka; Jan Zuna
Journal:  Blood       Date:  2017-03-22       Impact factor: 22.113

5.  Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.

Authors:  W Zeijlemaker; A Kelder; Y J M Oussoren-Brockhoff; W J Scholten; A N Snel; D Veldhuizen; J Cloos; G J Ossenkoppele; G J Schuurhuis
Journal:  Leukemia       Date:  2015-09-16       Impact factor: 11.528

Review 6.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

7.  Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.

Authors:  M J Pongers-Willemse; T Seriu; F Stolz; E d'Aniello; P Gameiro; P Pisa; M Gonzalez; C R Bartram; E R Panzer-Grümayer; A Biondi; J F San Miguel; J J van Dongen
Journal:  Leukemia       Date:  1999-01       Impact factor: 11.528

8.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

Review 9.  An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.

Authors:  Vittorio Nunes; Gianni Cazzaniga; A Biondi
Journal:  Expert Rev Mol Diagn       Date:  2017-09-21       Impact factor: 5.225

10.  Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

Authors:  C-H Pui; D Pei; S C Raimondi; E Coustan-Smith; S Jeha; C Cheng; W P Bowman; J T Sandlund; R C Ribeiro; J E Rubnitz; H Inaba; T A Gruber; W H Leung; J J Yang; J R Downing; W E Evans; M V Relling; D Campana
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.